EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Recursion Pharmaceuticals's Enterprise Value is MXN22,905 Mil.
Recursion Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-6,017 Mil. Therefore, Recursion Pharmaceuticals's EV-to-FCF for today is -3.81.
The historical rank and industry rank for Recursion Pharmaceuticals's EV-to-FCF or its related term are showing as below:
MEX:RXRX'
s EV-to-FCF Range Over the Past 10 Years
Min: -65.41 Med: -5.2 Max: -1.81
Current: -3.99
During the past 7 years, the highest EV-to-FCF of Recursion Pharmaceuticals was -1.81. The lowest was -65.41. And the median was -5.20.
MEX:RXRX's EV-to-FCF is ranked worse than 100% of 329
companies
in the Biotechnology industry
Industry Median: 15.85
vs MEX:RXRX: -3.99
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Recursion Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Recursion Pharmaceuticals's share price for today is MXN62.20.
Recursion Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-22.154.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Recursion Pharmaceuticals EV-to-FCF Related Terms
Recursion Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RXRX vs ABSI, GLUE, ANAB: EV-to-FCF Comparison
For the Biotechnology subindustry, Recursion Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recursion Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Recursion Pharmaceuticals's EV-to-FCF falls into.
Recursion Pharmaceuticals's current Enterprise Value is MXN22,905 Mil.
Recursion Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-6,017 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals (MEX:RXRX) has a EV-to-FCF of -3.81 as of Jul. 12, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Recursion Pharmaceuticals and its competitors. According to the industry distribution chart, Recursion Pharmaceuticals ranks #999999 out of 329 companies in the Biotechnology industry.
Is Recursion Pharmaceuticals' EV-to-FCF too high?
Recursion Pharmaceuticals' current EV-to-FCF is -3.81. Based on the distribution chart, Recursion Pharmaceuticals ranks #999999 out of 329 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Recursion Pharmaceuticals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' EV-to-FCF compare to ABSI and GLUE?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #999999 out of 329 companies for EV-to-FCF. This places Recursion Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 15.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.85, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Recursion Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recursion Pharmaceuticals's current EV-to-FCF is -3.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN73.63, compared to a current price of MXN62.20 — trading 15.5% below its estimated fair value. The current EV-to-FCF is -3.81. Recursion Pharmaceuticals' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current EV-to-FCF is -3.81 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN62.20 is trading 15.5% below its estimated GF Value™ of MXN73.63.
GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for MEX:RXRX:
EV-to-FCF: -3.81
GF Value™: MXN73.63 vs. price of MXN62.20 (15.5% below fair value)
No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
57GF Score
Get the complete analysis for MEX:RXRX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RXRX has been successfully added to your 
